Comparative Pharmacology
Head-to-head clinical analysis: FLEXICORT versus LOCORTEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLEXICORT versus LOCORTEN.
FLEXICORT vs LOCORTEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLEXICORT contains the active ingredient prednisolone, a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression, inhibition of phospholipase A2, and suppression of inflammatory mediators such as prostaglandins and leukotrienes.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit prostaglandin and leukotriene synthesis, reduce cytokine release, and suppress immune cell activation.
Flexicort is not a recognized drug name in authoritative pharmacological databases. Please verify the correct generic name. Assuming hydrocortisone: Typical adult dose is 10-40 mg orally daily in divided doses or as a single morning dose. Route: oral. Frequency: once or twice daily.
For mild to moderate dermatoses: Apply a thin film to affected area twice daily. For severe dermatoses: Apply a thin film to affected area three to four times daily. Topical use only. Not for ophthalmic use.
None Documented
None Documented
8–12 hours; clinical context: once-daily dosing maintains therapeutic levels, with steady-state achieved within 2–3 days.
100 hours (terminal). Clinical context: prolonged in hepatic impairment; single daily dosing sufficient for psoriasis.
Renal excretion of inactive metabolites accounts for 95% of elimination; biliary/fecal excretion is minimal at 5%.
Renal: ~75% (inactive metabolites); biliary/fecal: ~25%. <1% unchanged.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid